NTLA
Closed
Intellia Therapeutics Inc
9.88
+0.50 (+5.33%)
Last Update: 01 Jul 2025 23:27:00
Yesterday: 9.38
Day's Range: 8.98 - 10.125
Send
sign up or login to leave a comment!
When Written:
36.83
Intellia Therapeutics Inc. is a biotechnology company that focuses on the development of gene editing therapies using the CRISPR/Cas9 technology. The company was founded in 2014 and is based in Cambridge, Massachusetts. Intellia Therapeutics aims to use CRISPR/Cas9 to treat genetic diseases, such as sickle cell disease and beta thalassemia, by correcting the underlying genetic mutations.
The company has partnerships with Novartis and Regeneron Pharmaceuticals to develop gene editing therapies for various diseases. Intellia Therapeutics has also received funding from various sources, including venture capital firms and government grants.
Intellia Therapeutics is led by CEO John Leonard, who has more than 25 years of experience in the biotechnology industry. The company has a team of scientists, researchers, and executives who are focused on advancing the field of gene editing and developing innovative therapies for patients with genetic diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company has partnerships with Novartis and Regeneron Pharmaceuticals to develop gene editing therapies for various diseases. Intellia Therapeutics has also received funding from various sources, including venture capital firms and government grants.
Intellia Therapeutics is led by CEO John Leonard, who has more than 25 years of experience in the biotechnology industry. The company has a team of scientists, researchers, and executives who are focused on advancing the field of gene editing and developing innovative therapies for patients with genetic diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








